Foliglurax


Foliglurax is a positive allosteric modulator of the metabotropic glutamate receptor 4 which is under development by Prexton Therapeutics for the treatment of Parkinson's disease. As of July 2017, it is in phase II clinical trials.
ic form of foliglurax.